Allergan, Molecular Partners move forward with its quarterly dosed anti-VEGF treatment

Allergan and Molecular Partners’s Abicipar pegol DARPin therapy was accepted by FDA in the USA, and the European Medicines Agency (EMA) has validated a Marketing Authorisation Application (MAA), for patients with neovascular (wet) age-related macular degeneration (nAMD).

Read more

Molecular Partners, Allergan to file abicipar BLA in USA in the first half of 2019

Allergan and Molecular Partners revealed Tuesday the topline safety results from MAPLE, study which enrolled 123 age-related Neovascular Macular Degeneration (nAMD) patients and evaluated the safety of abicipar produced via a modified manufacturing process, which showed lower incidence and type of IOI.

Read more

Allergan with positive topline results for Bimatoprost implant for reduction of IOP

Allergan announced positive 3-month topline results from the second pivotal clinical trial of Bimatoprost SR, a first-in-class sustained-release, biodegradable implant for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension, while the global pharmaceutical leader noted the positive results from the first Phase 3 trial were reported in June 2018.

Read more